Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03184870 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 332
- Enrollment target
NCT03184870 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 332 participants.
The verdict
NCT03184870, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 332 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.
Interventions
- DRUG Gemcitabine
- BIOLOGICAL Nivolumab
- DRUG Nab-paclitaxel
- DRUG 5-fluorouracil (5-FU)
- DRUG BMS-813160
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2017-08-08 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03184870
The ClinicalTrials.gov registry entry for NCT03184870 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gemcitabine is the first listed.
NCT03184870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03184870 about?
NCT03184870 is a clinical study titled "A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.
What is the current status of trial NCT03184870?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 332 participants. The study started on 2017-08-08. Estimated completion is 2023-06-14.
What interventions are being tested in trial NCT03184870?
The interventions under investigation include: Gemcitabine (DRUG), Nivolumab (BIOLOGICAL), Nab-paclitaxel (DRUG), 5-fluorouracil (5-FU) (DRUG), BMS-813160 (DRUG).
Who is sponsoring clinical trial NCT03184870?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.